YPOG advises investors on € 21 million round for EvlaBio

Düsseldorf/ Zurich (CH) / Berlin — YPOG advi­sed a consor­tium of inves­tors led by Kurma Part­ners on the EUR 21 million finan­cing round of the biotech company Evla­Bio. The finan­cing round was led by Kurma Part­ners, toge­ther with Boeh­rin­ger Ingel­heim Venture Fund, AdBio Part­ners, HTGF and NRW.BANK.

With the new funds, Evla­Bio will advance the deve­lo­p­ment of its lead candi­date — a novel mono­clonal anti­body targe­ting the FGF23/FGFR4 signal­ing cascade, a key driver of cardiac remo­de­ling in pati­ents with chro­nic kidney dise­ase (CKD). The therapy speci­fi­cally targets the treat­ment of left ventri­cu­lar hyper­tro­phy, a common and severe compli­ca­tion of CKD. 

Hadrien Bouchez (photo © Kurma), Part­ner at Kurma Part­ners: “The team’s precli­ni­cal data and scien­ti­fic foun­da­tion are impres­sive. Evla­Bio addres­ses a highly rele­vant medi­cal need that has not yet been adequa­tely addressed.” 

Evla­Bio is a life science company focu­sed on the deve­lo­p­ment of first-in-class thera­peu­tics for cardio­vas­cu­lar and cardio­re­nal dise­a­ses. The lead program addres­ses the FGFR4/FGF23 signal­ing cascade, which is a key driver of cardiac remo­de­ling in chro­nic kidney dise­ase. By deve­lo­ping novel mecha­nisms based on sound science, Evla­Bio aims to create new treat­ment para­digms for CKD pati­ents with high unmet medi­cal need. 

Our colle­agues at Walder Wyss supported the inves­tor consor­tium on Swiss legal and tax issues.

Advi­sor to the inves­tor consor­tium: YPOG

Dr. Martin Scha­per (Tran­sac­tions), Part­ner, Berlin
Jörg Schr­ade (Tax), Part­ner, Munich
Dr. Bene­dikt Flöter (IP/IT/Data Protec­tion), Part­ner, Hamburg
Ciro D’Ame­lio (Tran­sac­tions), Asso­ciate, Berlin
Chris­toph Cordes (IP/IT/Data Protec­tion), Asso­ciate, Berlin
Boris Schin­zel (Tran­sac­tions), Asso­ciate, Berlin
Ninetta Klein­dienst (Tax), Asso­ciate, Munich

www.ypog.com